First TB Drug In 40 Years Spurs Warnings Of India's Antibiotics Excesses
This article was originally published in PharmAsia News
Executive Summary
The first new tuberculosis drug in 40 years, by a Johnson & Johnson subsidiary, is considered likely to face a tough approval process in India because of the greater threat it could be over-used, leading more quickly to resistant forms of the bacteria.